Table 4 Selected trials for KRAS G12C mutant NSCLC
From: Oncogenic alterations in advanced NSCLC: a molecular super-highway
Trial | Clinical trials ID | Phase | Treatments | Objective response rate (%) | Median progression-free survival (months) | Median overall survival (months) |
|---|---|---|---|---|---|---|
CodeBreak 100 | NCT03600883 | 1/2 | Sotorasib | 32 | 6.3 | 12.5 |
Krystal-1 | NCT03785249 | 1/2 | Adagrasib | 42.9 | 6.5 | 12.6 |
CodeBreak 200 | NCT04303780 | 3 | Sotorasib vs docetaxel | 28.1 vs 13.2 | 5.6 vs 4.5 (HR 0.66) | 10.6 vs 11.3 |